Jasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at Royal Bank of Canada

Royal Bank of Canada began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $70.00 price target on the stock.

A number of other brokerages have also recently commented on JSPR. Oppenheimer restated an outperform rating and issued a $80.00 price target on shares of Jasper Therapeutics in a research report on Thursday, March 7th. TD Cowen assumed coverage on Jasper Therapeutics in a research report on Monday, March 18th. They issued an outperform rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $64.00.

Jasper Therapeutics Stock Performance

JSPR stock opened at $29.36 on Thursday. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.00. The business’s 50-day moving average is $20.12 and its two-hundred day moving average is $11.56. The company has a market cap of $442.16 million, a price-to-earnings ratio of -4.74 and a beta of 2.18.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.15. Equities analysts predict that Jasper Therapeutics will post -5 earnings per share for the current year.

Insider Buying and Selling

In other Jasper Therapeutics news, major shareholder Velan Capital Investment Manag bought 350,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average price of $12.95 per share, for a total transaction of $4,532,500.00. Following the completion of the transaction, the insider now owns 1,188,500 shares of the company’s stock, valued at approximately $15,391,075. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.90% of the stock is currently owned by company insiders.

Institutional Trading of Jasper Therapeutics

Several institutional investors have recently made changes to their positions in JSPR. Renaissance Technologies LLC purchased a new stake in shares of Jasper Therapeutics during the first quarter worth about $39,000. State Street Corp bought a new position in Jasper Therapeutics during the first quarter valued at approximately $77,000. UBS Group AG boosted its stake in Jasper Therapeutics by 3,294.6% during the third quarter. UBS Group AG now owns 188,026 shares of the company’s stock valued at $148,000 after buying an additional 182,487 shares during the last quarter. Citadel Advisors LLC boosted its stake in Jasper Therapeutics by 3.8% during the third quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company’s stock valued at $2,448,000 after buying an additional 112,913 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Jasper Therapeutics by 10.3% during the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company’s stock valued at $418,000 after buying an additional 49,559 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.